Drug Trial Radar · NCT00405964
Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Last checked: Nov 20, 2026Latest source record: May 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
716
Actual
Start
Sep 2006
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)
Conditions
- Allergic Rhinitis
Interventions
5-mg DesloratadineDrug
5-mg Desloratadine tablet, once daily for 12 weeks
Placebo tabletDrug
Placebo tablet, once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of TreatmentTime frame: Baseline and Days 1-29
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.